Literature DB >> 26791363

Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.

Emily L Heil1, J Kristie Johnson2.   

Abstract

In 2010, the Clinical and Laboratory Standards Institute (CLSI) lowered the MIC breakpoints for many beta-lactam antibiotics to enhance detection of known resistance amongEnterobacteriaceae The decision to implement these new breakpoints, including the changes announced in both 2010 and 2014, can have a significant impact on both microbiology laboratories and antimicrobial stewardship programs. In this commentary, we discuss the changes and how implementation of these updated CLSI breakpoints requires partnership between antimicrobial stewardship programs and the microbiology laboratory, including data on the impact that the changes had on antibiotic usage at our own institution.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Mesh：

Substances：

Year:  2016        PMID： 26791363      PMCID： PMC4809933          DOI： 10.1128/JCM.02424-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.

Authors:  Michael Hombach; Guido V Bloemberg; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2011-12-13       Impact factor: 5.790

2.  Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.

Authors:  Dror Marchaim; Bharath Sunkara; Paul R Lephart; Uma Mahesh Gudur; Ashish Bhargava; Ryan P Mynatt; Jing J Zhao; Suchitha Bheemreddy; Kayoko Hayakawa; Teena Chopra; Sorabh Dhar; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2012-06-11       Impact factor: 3.254

3.  Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers?

Authors:  Lilian M Abbo; Sara E Cosgrove; Paul S Pottinger; Margaret Pereyra; Ronda Sinkowitz-Cochran; Arjun Srinivasan; David J Webb; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2013-05-31       Impact factor: 9.079

4.  Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.

Authors:  Po-Yu Liu; Zhi-Yuan Shi; Kwong-Chung Tung; Ching-Lin Shyu; Kun-Wei Chan; Jai-Wen Liu; Zong-Yen Wu; Chih-Chuan Kao; Yi-Ching Huang; Chin-Fu Lin
Journal:  J Infect Dev Ctries       Date:  2014-03-13       Impact factor: 0.968

5.  Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.

Authors:  Carla S McWilliams; Susan Condon; Rebecca M Schwartz; Christine C Ginocchio
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

6.  Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

Authors:  Nan-Yao Lee; Ching-Chi Lee; Wei-Han Huang; Ko-Chung Tsui; Po-Ren Hsueh; Wen-Chien Ko
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

Review 7.  Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Authors:  Michael N Dudley; Paul G Ambrose; Sujata M Bhavnani; William A Craig; Mary Jane Ferraro; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2013-01-18       Impact factor: 9.079

8.  Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.

Authors:  Ioulia Kristo; Vassiliki Pitiriga; Aggeliki Poulou; Olympia Zarkotou; Maria Kimouli; Spyros Pournaras; Athanassios Tsakris
Journal:  Int J Antimicrob Agents       Date:  2013-02-01       Impact factor: 5.283

Review 9.  Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Hien M Nguyen; Kileen L Shier; Christopher J Graber
Journal:  J Antimicrob Chemother       Date:  2013-11-20       Impact factor: 5.790

10.  Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.

Authors:  Cheol-In Kang; Min Kyeong Cha; So Hyun Kim; Yu Mi Wi; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  Int J Antimicrob Agents       Date:  2014-03-18       Impact factor: 5.283
View more
  15 in total

Review 1.  Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship.

Authors:  Philippe Morency-Potvin; David N Schwartz; Robert A Weinstein
Journal:  Clin Microbiol Rev       Date:  2016-12-14       Impact factor: 26.132

Review 2.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

3.  Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.

Authors:  Christian M Gill; Elif Aktaş; Wadha Alfouzan; Lori Bourassa; Adrian Brink; Carey-Ann D Burnham; Rafael Canton; Yehuda Carmeli; Marco Falcone; Carlos Kiffer; Anna Marchese; Octavio Martinez; Spyros Pournaras; Harald Seifert; Abrar K Thabit; Maria Virginia Villegas; Lars F Westblade; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

4.  Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision.

Authors:  Ying Wang; Xinping Zhang; Xuemei Wang; Xiaoquan Lai
Journal:  Infect Drug Resist       Date:  2021-08-31       Impact factor: 4.003

5.  Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests.

Authors:  Laura N Cwengros; Ryan P Mynatt; Tristan T Timbrook; Robert Mitchell; Hossein Salimnia; Paul Lephart; Jason M Pogue
Journal:  Open Forum Infect Dis       Date:  2020-07-02       Impact factor: 3.835

6.  Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.

Authors:  Ying Sun; Xueyuan Liao; Zhigang Huang; Yaliu Xie; Yanbin Liu; Cuicui Ma; Boguang Jiang; Li Zhang; Yuhang Yan; Guobo Li; Xingjun Cheng; Qi Yin; Charles Z Ding; Liang Shen; Jian Li; Shuhui Chen; Yuquan Wei; Zhenling Wang; Xiawei Wei
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 7.  En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Authors:  Pierre-Louis Toutain; Alain Bousquet-Mélou; Peter Damborg; Aude A Ferran; Dik Mevius; Ludovic Pelligand; Kees T Veldman; Peter Lees
Journal:  Front Microbiol       Date:  2017-12-15       Impact factor: 5.640

Review 8.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

9.  Pneumonia in hospitalized neurologic patients: trends in pathogen distribution and antibiotic susceptibility.

Authors:  Han Sang Lee; Jangsup Moon; Hye-Rim Shin; Seon Jae Ahn; Tae-Joon Kim; Jin-Sun Jun; Soon-Tae Lee; Keun-Hwa Jung; Kyung-Il Park; Ki-Young Jung; Manho Kim; Sang Kun Lee; Kon Chu
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-01       Impact factor: 4.887

Review 10.  We Cannot Do It Alone: The Intersection of Public Health, Public Policy, and Clinical Microbiology.

Authors:  Rose A Lee; James E Kirby
Journal:  Clin Lab Med       Date:  2019-07-06       Impact factor: 1.935
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.